Jove
Visualize
Contact Us
JoVE
x logofacebook logolinkedin logoyoutube logo
ABOUT JoVE
OverviewLeadershipBlogJoVE Help Center
AUTHORS
Publishing ProcessEditorial BoardScope & PoliciesPeer ReviewFAQSubmit
LIBRARIANS
TestimonialsSubscriptionsAccessResourcesLibrary Advisory BoardFAQ
RESEARCH
JoVE JournalMethods CollectionsJoVE Encyclopedia of ExperimentsArchive
EDUCATION
JoVE CoreJoVE BusinessJoVE Science EducationJoVE Lab ManualFaculty Resource CenterFaculty Site
Terms & Conditions of Use
Privacy Policy
Policies

Filters

Susan Erickson

Showing results (1-10 of 22) with videos related to

Pageof 3
Sort By:
Annals of the New York Academy of Sciences|July 15, 2004
Postnatal development of prefrontal inhibitory circuits and the pathophysiology of cognitive dysfunction in schizophreniaDavid A Lewis, Dianne Cruz, Stephen Eggan, et al.
Journal of Hematology & Oncology|August 9, 2018
Evaluation of an alternative ruxolitinib dosing regimen in patients with myelofibrosis: an open-label phase 2 studyMoshe Talpaz, Susan Erickson-Viitanen, Kevin Hou, et al.
Bioorganic & Medicinal Chemistry Letters|October 10, 2002
P1 Phenethyl peptide boronic acid inhibitors of HCV NS3 proteaseE Scott Priestley, Indawati De Lucca, Bahman Ghavimi, et al.
American Journal of Ophthalmology|December 8, 2019
Perspective on Systematic Medical Literature Reviews and Meta-AnalysesJay S Pepose, Gary N Foulks, J Daniel Nelson, et al.
Alzheimer'S & Dementia : the Journal of the Alzheimer'S Association|December 24, 2025
Basic Science and PathogenesisJosh Krivinko, Susan Erickson, Akayla Lewin, et al.
Leukemia Research|May 21, 2013
Progressive burden of myelofibrosis in untreated patients: assessment of patient-reported outcomes in patients randomized to placebo in the COMFORT-I studyRuben A Mesa, Alan Shields, Thomas Hare, et al.
Clinical Lung Cancer|April 24, 2018
A Placebo-Controlled Phase II Study of Ruxolitinib in Combination With Pemetrexed and Cisplatin for First-Line Treatment of Patients With Advanced Nonsquamous Non-Small-Cell Lung Cancer and Systemic InflammationGiuseppe Giaccone, Rachel E Sanborn, Saiama N Waqar, et al.
Antiviral Chemistry & Chemotherapy|June 7, 2003
HIV-1 resistance profile of the novel nucleoside reverse transcriptase inhibitor beta-D-2',3'-dideoxy-2',3'-didehydro-5-fluorocytidine (Reverset)Romas Geleziunas, Karen Gallagher, Hangchun Zhang, et al.
Antiviral Chemistry & Chemotherapy|June 7, 2003
Cellular pharmacology of D-d4FC, a nucleoside analogue active against drug-resistant HIVSusan Erickson-Viitanen, Jing-Tao Wu, Guoen Shi, et al.
Cancer|April 12, 2011
Evaluating the serial use of the Myelofibrosis Symptom Assessment Form for measuring symptomatic improvement: performance in 87 myelofibrosis patients on a JAK1 and JAK2 inhibitor (INCB018424) clinical trialRuben A Mesa, Hagop Kantarjian, Ayalew Tefferi, et al.
Pageof 3

Showing results (1-10 of 22) with videos related to

Sort By:
Pageof 3
Annals of the New York Academy of Sciences|July 15, 2004
Postnatal development of prefrontal inhibitory circuits and the pathophysiology of cognitive dysfunction in schizophreniaDavid A Lewis, Dianne Cruz, Stephen Eggan, et al.
Journal of Hematology & Oncology|August 9, 2018
Evaluation of an alternative ruxolitinib dosing regimen in patients with myelofibrosis: an open-label phase 2 studyMoshe Talpaz, Susan Erickson-Viitanen, Kevin Hou, et al.
Bioorganic & Medicinal Chemistry Letters|October 10, 2002
P1 Phenethyl peptide boronic acid inhibitors of HCV NS3 proteaseE Scott Priestley, Indawati De Lucca, Bahman Ghavimi, et al.
American Journal of Ophthalmology|December 8, 2019
Perspective on Systematic Medical Literature Reviews and Meta-AnalysesJay S Pepose, Gary N Foulks, J Daniel Nelson, et al.
Alzheimer'S & Dementia : the Journal of the Alzheimer'S Association|December 24, 2025
Basic Science and PathogenesisJosh Krivinko, Susan Erickson, Akayla Lewin, et al.
Leukemia Research|May 21, 2013
Progressive burden of myelofibrosis in untreated patients: assessment of patient-reported outcomes in patients randomized to placebo in the COMFORT-I studyRuben A Mesa, Alan Shields, Thomas Hare, et al.
Clinical Lung Cancer|April 24, 2018
A Placebo-Controlled Phase II Study of Ruxolitinib in Combination With Pemetrexed and Cisplatin for First-Line Treatment of Patients With Advanced Nonsquamous Non-Small-Cell Lung Cancer and Systemic InflammationGiuseppe Giaccone, Rachel E Sanborn, Saiama N Waqar, et al.
Antiviral Chemistry & Chemotherapy|June 7, 2003
HIV-1 resistance profile of the novel nucleoside reverse transcriptase inhibitor beta-D-2',3'-dideoxy-2',3'-didehydro-5-fluorocytidine (Reverset)Romas Geleziunas, Karen Gallagher, Hangchun Zhang, et al.
Antiviral Chemistry & Chemotherapy|June 7, 2003
Cellular pharmacology of D-d4FC, a nucleoside analogue active against drug-resistant HIVSusan Erickson-Viitanen, Jing-Tao Wu, Guoen Shi, et al.
Cancer|April 12, 2011
Evaluating the serial use of the Myelofibrosis Symptom Assessment Form for measuring symptomatic improvement: performance in 87 myelofibrosis patients on a JAK1 and JAK2 inhibitor (INCB018424) clinical trialRuben A Mesa, Hagop Kantarjian, Ayalew Tefferi, et al.
Pageof 3